Loading Curie Briefs...
Getting the latest healthcare news for you
Getting the latest healthcare news for you
The AMUNDSEN trial tested whether giving heart attack patients a PCSK9 inhibitor (evolocumab) right before their procedure could deliver faster clinical benefits — and the answer was a mixed bag. LDL cholesterol plummeted dramatically with early treatment, but death and cardiovascular hospitalization rates at 1 year were virtually identical between groups. Experts say the trial was likely too short and too small to detect a meaningful clinical difference.
The AMUNDSEN trial set out to answer two questions: Can starting evolocumab (Repatha) in the cath lab before PCI improve long-term LDL control in acute MI patients, and could early PCSK9 inhibition deliver rapid pleiotropic benefits — similar to what was once hoped for with statins? The answer to the first question was a resounding yes; the second, not so much.
Among 2,161 high-risk MI patients randomized to immediate evolocumab or standard care, 82% of the early-treatment group hit guideline-recommended LDL targets at 1 year versus just 40% in the standard-care group. But all-cause death or unplanned cardiovascular hospitalization at 12 months was nearly identical between groups (14.6% vs. 15.4%), leaving the "strike early, strike strong" strategy without a clinical win — for now.
Experts caution against reading too much into the neutral outcome result. The trial's 1-year follow-up is widely seen as too short for LDL-lowering benefits to fully materialize, and the modest sample size limited statistical power. The larger EVOLVE-MI trial, with 6,000+ participants and a 3.5–4 year follow-up, is expected to provide more definitive answers.
By the Numbers:
Why it matters: AMUNDSEN reinforces that aggressive, early LDL-lowering is achievable — but proving it saves lives requires longer studies. The trial also highlights a real-world gap: hospitalization may be the only window many patients have to access PCSK9 inhibitor therapy.
